GlassScriptPhysician profile
Robin Korin
NPI 1063895118
$5,718.33
in general payments reported to CMS, 2019-2025
25 companies · $33.50 in 2025
The $33.50 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,735 · 2022: $2,313 · 2023: $1,622 · 2024: $15.95 · 2025: $33.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,025.92 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $556.91 | 2021-2023 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $432.05 | 2021-2023 | Entyvio, Gattex |
| Amgen INC. | $361.82 | 2021-2023 | Avsola, Amjevita |
| Pfizer INC. | $228.01 | 2021-2023 | |
| Ardelyx, INC. | $220.60 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $211.59 | 2021-2023 | Zinplava, Dificid |
| Janssen Biotech, INC. | $207.94 | 2021-2025 | Stelara, Tremfya |
| Redhill Biopharma INC. | $206.45 | 2021-2022 | |
| Gilead Sciences, INC. | $196.94 | 2021-2023 | |
| Genzyme Corporation | $184.54 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $127.72 | 2021-2023 | Ocaliva |
| Qol Medical, LLC | $127.42 | 2022-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $123.90 | 2022-2023 | Dupixent |
| Daiichi Sankyo INC. | $121.71 | 2021-2023 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $70.18 | 2021-2023 | Givlaari |
| Celgene Corporation | $55.68 | 2021-2023 | Zeposia |
| Organon LLC | $48.09 | 2022-2023 | Renflexis |
| Ironwood Pharmaceuticals, INC | $42.43 | 2021-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $40.81 | 2022 | |
| Nestle Healthcare Nutrition INC. | $38.77 | 2022 | |
| Currax Pharmaceuticals LLC | $28.22 | 2021-2022 | |
| Intra-Sana Laboratories | $25.67 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Fresenius Kabi USA, LLC | $19.78 | 2023 | Idacio |
| Braintree Laboratories, INC. | $15.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Korin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.